Armstrong Advisory Group Inc. Raises Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Armstrong Advisory Group Inc. raised its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 14.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,606 shares of the biopharmaceutical company’s stock after purchasing an additional 200 shares during the period. Armstrong Advisory Group Inc.’s holdings in Gilead Sciences were worth $148,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also bought and sold shares of the company. nVerses Capital LLC bought a new position in shares of Gilead Sciences during the 3rd quarter worth $25,000. Valued Wealth Advisors LLC boosted its position in Gilead Sciences by 101.9% during the third quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 161 shares during the period. Strategic Investment Solutions Inc. IL bought a new stake in shares of Gilead Sciences in the second quarter valued at approximately $33,000. Cedar Wealth Management LLC lifted its stake in shares of Gilead Sciences by 51.6% during the 2nd quarter. Cedar Wealth Management LLC now owns 470 shares of the biopharmaceutical company’s stock valued at $32,000 after buying an additional 160 shares in the last quarter. Finally, Friedenthal Financial bought a new position in Gilead Sciences in the 3rd quarter worth approximately $50,000. 83.67% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

GILD has been the topic of a number of analyst reports. JPMorgan Chase & Co. boosted their target price on shares of Gilead Sciences from $100.00 to $105.00 and gave the company an “overweight” rating in a report on Thursday, November 7th. Mizuho increased their price objective on Gilead Sciences from $90.00 to $100.00 and gave the stock an “outperform” rating in a report on Thursday, November 21st. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $80.00 target price on shares of Gilead Sciences in a report on Wednesday, December 11th. Truist Financial increased their price target on shares of Gilead Sciences from $83.00 to $97.00 and gave the stock a “hold” rating in a report on Friday, November 8th. Finally, Daiwa America raised shares of Gilead Sciences to a “hold” rating in a report on Monday, November 18th. Eleven equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and four have issued a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $97.96.

Gilead Sciences Trading Down 0.8 %

NASDAQ GILD opened at $91.65 on Friday. The firm has a market cap of $114.22 billion, a PE ratio of 1,018.33, a price-to-earnings-growth ratio of 1.27 and a beta of 0.18. Gilead Sciences, Inc. has a 1-year low of $62.07 and a 1-year high of $98.90. The stock has a 50-day moving average of $91.97 and a 200-day moving average of $83.76. The company has a current ratio of 1.26, a quick ratio of 1.10 and a debt-to-equity ratio of 1.24.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, beating analysts’ consensus estimates of $1.58 by $0.44. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The firm had revenue of $7.55 billion during the quarter, compared to analyst estimates of $7.01 billion. During the same quarter in the prior year, the firm posted $2.29 earnings per share. The business’s quarterly revenue was up 7.0% compared to the same quarter last year. As a group, sell-side analysts forecast that Gilead Sciences, Inc. will post 4.36 EPS for the current year.

Gilead Sciences Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, December 30th. Stockholders of record on Friday, December 13th were paid a dividend of $0.77 per share. This represents a $3.08 annualized dividend and a dividend yield of 3.36%. The ex-dividend date of this dividend was Friday, December 13th. Gilead Sciences’s dividend payout ratio (DPR) is 3,422.22%.

Insider Activity

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 248,645 shares of the company’s stock in a transaction that occurred on Friday, November 29th. The stock was sold at an average price of $92.76, for a total transaction of $23,064,310.20. Following the completion of the transaction, the chief financial officer now owns 138,919 shares of the company’s stock, valued at $12,886,126.44. This represents a 64.16 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Merdad Parsey sold 25,590 shares of Gilead Sciences stock in a transaction that occurred on Wednesday, November 6th. The stock was sold at an average price of $91.50, for a total value of $2,341,485.00. Following the completion of the sale, the insider now owns 99,599 shares in the company, valued at approximately $9,113,308.50. This represents a 20.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 456,234 shares of company stock valued at $42,130,461. Insiders own 0.16% of the company’s stock.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.